Overview of iron chelation therapy with desferrioxamine and deferiprone

Maria D. Cappellini, Khaled M. Musallam, Ali T. Taher

Research output: Contribution to journalArticlepeer-review


Chronic iron overload from frequent blood transfusions to treat patients with severe anemias leads to significant morbidity and mortality. Although desferrioxamine, the current standard of care, is an effective iron chelator with long-term evidence, it requires tedious subcutaneous infusion that reflects negatively on patient compliance. Deferiprone opened the horizon for an era of oral iron chelators. Although collective evidence proved its efficacy, safety issues are still of high concern and require regular monitoring. The experience with these two drugs helps better delineate the optimal goals of iron chelation therapy and the ideal iron chelator.

Original languageEnglish
Issue numberSUPPL. 1
Publication statusPublished - 2009


  • Deferiprone
  • Deferoxamine
  • Desferrioxamine
  • Iron chelation
  • Iron overload
  • L1

ASJC Scopus subject areas

  • Hematology
  • Genetics(clinical)
  • Clinical Biochemistry
  • Biochemistry, medical


Dive into the research topics of 'Overview of iron chelation therapy with desferrioxamine and deferiprone'. Together they form a unique fingerprint.

Cite this